Impedimed Ltd logo

Impedimed Ltd

NEW
OTCPK:IPDQF (USA)  
$ 0.0051 -0.0026 (-33.77%) 10:08 PM EST
At Loss
P/B:
1.25
Market Cap:
$ 12.63M
Enterprise V:
$ 14.49M
Volume:
249.89K
Avg Vol (2M):
64.49K
Trade In:
Volume:
249.89K
At Loss
Avg Vol (2M):
64.49K

Business Description

Description
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
0.87
Equity-to-Asset
0.24
Debt-to-Equity
2.39
Debt-to-EBITDA
-1.35
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-12.2
Distress
Grey
Safe
Beneish M-Score
-4.47
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
25.84
9-Day RSI
32.13
14-Day RSI
34.61
3-1 Month Momentum %
-50
6-1 Month Momentum %
-68.18
12-1 Month Momentum %
-77.85

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
3.74
Quick Ratio
3.41
Cash Ratio
2.75
Days Inventory
248.95
Days Sales Outstanding
71.69
Days Payable
311.76

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-4.5
Shareholder Yield %
-92.51

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin %
86.18
Operating Margin %
-166.18
Net Margin %
-170.87
EBITDA Margin %
-111.97
FCF Margin %
-117.49
OCF Margin %
-111.37
ROE %
-118.25
ROA %
-61.34
ROIC %
-128.57
3-Year ROIIC %
-122.18
ROC (Joel Greenblatt) %
-1522.57
ROCE %
-60.34
Moat Score
4
Tariff Resilience Score
5

Financials

IPDQF's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:IPDQF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Impedimed Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 9.387
EPS (TTM) ($) -0.008
Beta -0.4478
3-Year Sharpe Ratio -0.03
3-Year Sortino Ratio -0.06
Volatility % 142.18
14-Day RSI 34.61
14-Day ATR ($) 0.000462
20-Day SMA ($) 0.006248
12-1 Month Momentum % -77.85
52-Week Range ($) 0.0045 - 0.0514
Shares Outstanding (Mil) 3,659.81

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Impedimed Ltd Filings

Filing Date Document Date Form
No Filing Data

Impedimed Ltd Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Impedimed Ltd Frequently Asked Questions

What is Impedimed Ltd(IPDQF)'s stock price today?
The current price of IPDQF is $0.01. The 52 week high of IPDQF is $0.05 and 52 week low is $0.00.
When is next earnings date of Impedimed Ltd(IPDQF)?
The next earnings date of Impedimed Ltd(IPDQF) is .
Does Impedimed Ltd(IPDQF) pay dividends? If so, how much?
Impedimed Ltd(IPDQF) does not pay dividend.

Guru Commentaries on OTCPK:IPDQF

No articles.

Press Release

Subject Date
New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival 2022-12-15
ImpediMed Extends Contract for AstraZeneca for Use of the SOZO Digital Health Platform in Clinical Trial of Patients with Chronic Kidney Disease 2022-11-16
ImpediMed Reaches Milestone of 500,000 Patient Tests Performed with the SOZO Digital Health Platform 2022-11-02
Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer-Related Lymphedema 2022-10-26
New Data Confirms Early Detection and Intervention of Lymphedema Improves Quality of Life for Breast Cancer Patients Who Avoid Chronic Lymphedema 2022-10-20
New Bone Data Showing Strong Correlation between ImpediMed's SOZO and DXA in Cancer Patients Presented at 39th Annual Miami Breast Cancer Conference 2022-03-07
New Data Evaluating ImpediMed's SOZO® Digital Health Platform to Assess Bone in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference 2022-02-15
New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed's L-Dex® Technology and Intervention 2022-02-01
ImpediMed Launches "Lymphedema Can't" Educational Campaign for Breast Cancer Patients and Survivors 2021-09-30
ImpediMed Announces Presentation at Heart Failure Society of America Annual Scientific Meeting That Demonstrates Utility of SOZO® Digital Health Platform for Heart Failure Patients 2021-09-10
10/Page

Articles on Impedimed Ltd

No articles.

Headlines

See More
  • 1
No news.
  • 1